[{"from": "human", "value": "Describe this molecule. [C][O][C][=C][C][=Branch2][Ring2][=N][=C][Branch2][Ring2][Branch2][C][=Branch1][Branch1][=C][Ring1][=Branch1][Cl][C][=C][C][=C][N][=C][Branch1][=Branch2][N][=C][Ring1][=Branch1][C][=C][Ring1][#Branch2][N][C@@H1][C][O][C][C][C@@H1][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][Cl][O][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon oral administration, fisogatinib specifically binds to and blocks the binding of the ligand FGF19 to FGFR4. This prevents the activation of FGFR4, inhibits FGFR4-mediated signaling and leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase and is involved in tumor cell proliferation, differentiation, angiogenesis, and survival. FGF19 is overexpressed by certain tumor cell types."}]